What is Amjevita Subcutaneous
Amjevita Subcutaneous is a prescription medication used to treat rheumatoid arthritis and psoriatic arthritis. It is a tumor necrosis factor (TNF) inhibitor that works by blocking the action of TNF, a protein that causes inflammation and damage to the joints.
Amjevita Subcutaneous is available as a self-injectable medication that is given by injection under the skin (subcutaneously). It is available as a pre-filled syringe or a pen-like injector.
Amjevita Subcutaneous is a brand name medication. It is manufactured by AbbVie.
Benefits of Amjevita Subcutaneous
and Its Uses.
Amjevita Subcutaneous is a recombinant humanized monoclonal antibody that is used for the treatment of moderate to severe rheumatoid arthritis (RA) in adults. It is administered as a subcutaneous injection.
RA is a chronic, autoimmune inflammatory disorder that affects the joints. It is characterized by pain, stiffness, swelling, and loss of function in the joints. Amjevita Subcutaneous is a biologic agent that helps to reduce inflammation and improve function in the joints. It is an effective treatment for RA that can provide relief from symptoms and improve quality of life.
Side Effects and Dosage of Amjevita Subcutaneous
Amjevita Subcutaneous is a prescription drug that is used to treat certain autoimmune diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. It is a tumor necrosis factor (TNF) blocker that works by blocking the action of TNF, a protein that is involved in the inflammation and damage of tissues.
The most common side effects of Amjevita Subcutaneous include upper respiratory infections, headaches, rash, and nausea. It is important to report any signs of infection, including fever, cough, shortness of breath, or open sores to your healthcare provider.
Amjevita Subcutaneous is available in a variety of dosages, depending on the condition being treated. It is typically injected under the skin (subcutaneously) two to four times per week